AI Verdict
IOBT has stronger fundamentals based on our AI analysis.
IOBT vs INVE Fundamental Comparison
| Metric | IOBT | INVE |
|---|---|---|
| Revenue | N/A | $21.5M |
| Net Income | $-57.0M | $-18.0M |
| Net Margin | N/A | -83.8% |
| ROE | -6,258.6% | -12.8% |
| ROA | -142.7% | -11.9% |
| Current Ratio | 2.01x | 15.19x |
| Debt/Equity | 18.29x | 0.07x |
| EPS | $-0.86 | $-0.79 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
IOBT vs INVE: Frequently Asked Questions
Is IOBT or INVE a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), IOBT has stronger fundamentals. IOBT is rated STRONG SELL (95% confidence) while INVE is rated STRONG SELL (92% confidence). This is not investment advice.
How does IOBT compare to INVE fundamentally?
IO Biotech, Inc. has ROE of -6,258.6% vs Identiv, Inc.'s -12.8%. Net margins are N/A vs -83.8% respectively.
Which stock pays higher dividends, IOBT or INVE?
IOBT has a dividend yield of N/A or no dividend while INVE has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in IOBT or INVE for long term?
For long-term investing, consider that IOBT has STRONG SELL rating with 95% confidence, while INVE has STRONG SELL rating with 92% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about IOBT vs INVE?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For IOBT vs INVE, the AI consensus favors IOBT based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.